VectivBio Seeks Slice Of Short Bowel Syndrome Market
As Offering Brings In $125m
The Switzerland-headquartered group believes it has a potentially best-in-class GLP-2 agonist on its hands with apraglutide, which has proved effective in a subgroup of patients that do not benefit from standard of care Gattex.
You may also be interested in...
With the acquisition of Swiss biotech firm in late June, Ironwood Pharmaceuticals has firmly positioned itself as a gastrointestinal-focused company.
Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.
Deal Snapshot: VectivBio is expanding its existing focus on rare diseases into inherited metabolic disorders, which affect about one in 800 live births and cause significant mortality in infants and young people.